Industry News

Guangdong's 'Spring Rain Action' Promotes Clinical Innovation in Medical Devices, Local OEMs Usher in New Transformation Opportunities

Guangdong's 'Spring Rain Action' Promotes Clinical Innovation in Medical Devices, Local OEMs Usher in New Transformation Opportunities

Policy Implementation: Guangdong Takes the Lead in Breaking Through Clinical Transformation of Medical Devices

In early July 2026, the Guangdong Provincial Department of Science and Technology, together with the Health Commission and the Medical Products Administration, launched the 'Spring Rain Action'—a special action plan focusing on clinical innovation and transformation of medical devices. The introduction of this policy stems from the long-standing structural problems facing Guangdong's medical device industry: strong R&D capabilities but low transformation efficiency, and scattered clinical trial resources that are disconnected from industry needs.

Guangdong's medical device industry accounts for a quarter of the national annual output value and boasts the country's most densely concentrated cluster of medical device enterprises. However, in the transformation chain from concept to product for innovative medical devices, difficult access to clinical trial resources, long cycles, and high costs have always been core bottlenecks. Many enterprises' innovative products are forced to be abandoned or shifted to low-threshold improved products because they cannot afford to wait for clinical trial scheduling.

The core measures of the 'Spring Rain Action' include three aspects:

First, building a clinical trial resource pool. Integrate clinical trial resources of tertiary hospitals and specialty hospitals in Guangdong Province, and establish a unified medical device clinical trial information platform. Enterprises can query the professional directions, equipment conditions, and scheduling of clinical trial centers of various hospitals through the platform, and submit clinical trial applications online, greatly shortening the docking cycle.

Second, an acceleration channel for innovative products. For Class II and Class III medical devices with core technological innovation, provide full-process guidance from product definition, type testing to clinical trials, equipped with 'one-on-one' regulatory consultants and technical mentors. The goal of this mechanism is to compress the average registration cycle of innovative devices from the current 18-24 months to 12-15 months.

Third, transformation subsidies. For innovative medical device products that complete clinical trials and obtain registration certificates, the provincial finance department provides special subsidies ranging from 500,000 to 2 million yuan to reduce the financial pressure on enterprises for clinical transformation.

What Does It Mean for OEM Enterprises?

On the surface, the direct beneficiaries of the 'Spring Rain Action' are innovative enterprises with independent R&D capabilities. But the deeper logic is: when more innovative products complete registration through the acceleration channel, what they need are OEM partners capable of undertaking large-scale production.

For leading OEM enterprises like Weitai Group, which is rooted in Guangdong and has four smart factories, this is a structural benefit.

From the production side, the production requirements for innovative medical devices are usually more complex than mature products—process parameters require stricter control, quality control standards are higher, and some products also require special packaging and sterilization processes. These requirements are exactly where OEM enterprises with Class 100,000 and Class 10,000 cleanrooms, Class 100 freeze-drying environments, and comprehensive quality management systems excel.

From the order side, innovative products need rapid scale-up after approval, and brand owners often do not build their own factories. The large-scale production capacity and delivery speed of OEM enterprises become key support for innovative products to seize the market.

Weitai's Innovation Transformation Practice

Weitai Group has years of practice in the innovation transformation of medical devices. Its self-built independent R&D laboratory is a typical case of transforming technological achievements into mass-produced products—from molecular design and expression purification of recombinant collagen to process development and large-scale production of freeze-dried preparations, forming a complete 'industry-university-research' transformation chain.

At present, Weitai has accumulated more than 12,000 mature formulas, 72 patents, and over 110 Class II medical device registration filings. These reserves are not only a reflection of production capacity but also proof of innovation transformation capability.

Under the policy framework of the 'Spring Rain Action', Weitai can further play two roles:

First, as a clinical trial partner. Before innovative medical devices enter mass production, they usually require small-batch trial production and process validation at OEM factories. Weitai's R&D center and pilot production lines can provide process scale-up services for innovative products from laboratory scale to production scale.

Second, as a undertaker of large-scale production. After innovative products are approved, mass production needs to be achieved in the shortest time. The daily production capacity of Weitai's four bases—1 million pairs of freeze-dried powder and 1 million masks—can quickly respond to brand owners' scale-up needs.

The Cluster Effect of Guangdong's Medical Device Industry

The launch of the 'Spring Rain Action' further consolidates Guangdong's leading position in the national medical device industry. Guangdong Province is forming three major medical device industry clusters centered on Shenzhen, Guangzhou, and Zhaoqing, covering the entire chain from raw material supply, R&D and design, clinical trials to large-scale production and logistics distribution.

The distribution of Weitai Group's four bases exactly covers this industrial corridor—the Guangzhou base undertakes mask and freeze-dried powder production, the Zhaoqing base undertakes part of the functions, and the Hunan base radiates to the central market. This industrial layout not only conforms to the supply chain advantages brought by the cluster effect but also meets the nearby delivery needs of national brand customers.

Forward-looking Layout

Facing the policy dividends brought by the 'Spring Rain Action', Weitai Group is preparing to undertake them from three aspects:

Continuous increase in technology reserves. In the core raw material fields such as recombinant collagen, sodium hyaluronate, and peptides, continue to invest in R&D and maintain deep technical accumulation in formulas and processes.

Expansion of registration service capabilities. Establish a professional regulatory registration team to provide cooperative brand owners with full-chain services from product definition, formula design, registration application to production release, reducing the entry threshold for innovative products.

Optimization of production capacity flexibility. On the basis of existing production capacity, reserve flexible production lines for small-batch trial production and rapid scale-up of innovative products, ensuring that innovative products are not delayed in market windows due to capacity issues.

Conclusion

The launch of the 'Spring Rain Action' marks a new stage in which Guangdong's medical device industry shifts from scale expansion to innovation-driven development. For OEM enterprises in the industry chain, whoever can earlier complete the role upgrade from 'capacity provider' to 'innovation transformation partner' will be able to take the initiative in the next round of industry reshuffling.

Weitai Group's choice is clear—not to be a passive capacity lessor, but to be a proactive innovation transformation platform. From formula to registration, from trial production to mass production, from quality control to delivery, full-chain participation and full-process responsibility. This is not a slogan, but the confidence built up by 25 years of industry experience and over 110 Class II medical device registration filings.

Data sources: Guangdong Provincial Department of Science and Technology 'Spring Rain Action' announcement, National Medical Products Administration classification adjustment announcement, corporate public information


About Weitai Group | OEM/ODM Contract Manufacturing Services

Weitai Group started in 2012, has been engaged in medical aesthetic functional skincare for many years, 25 years, and is a medical aesthetic skincare OEM/ODM contract manufacturer with many years in the industry. The four factories (Guangzhou, Hunan, Zhaoqing) cover a total area of over 150,000 square meters, with 50+ fully automatic production lines, holding over 110 Class II medical device registration filings, accumulating a mature formula library + mature formulas, and 72 patents.

Core contract manufacturing capabilities:

  • Medical dressings/masks (daily output 1 million pieces, Class II medical device certificate)
  • Freeze-dried powder (daily output 1 million pairs, developed by own R&D laboratory)
  • Essence serums/lotions and creams (full category of cosmetic products)
  • Medical gels/hemostatic materials (Class II medical device certificate)

Quality assurance: US GMPC + EU ISO22716 dual certification, 38 quality inspections, yield rate 99.99%. Has served hundreds of brands (including Chando, etc.).

Cooperation models: OEM processing with supplied materials | ODM private label customization | Shitaqi spot direct supply

Delivery capability: Regular 7-15 days, expedited 3-day shipment. Official website: www.weitaigd.com

← Back to News
Call Us
📞

Weitai Support

● Online
微肽智能客服

Hello, I'm Weitai Group's AI assistant

  • 25 years of OEM/ODM experience
  • 25 years of OEM/ODM experience
  • Extensive formula library
  • 110+ Class II device registrations

How can I help you?

WeChat QR Code

👆 Scan to add WeChat

WeChat ID: weitai-bioWeChat Consultation

Business Inquiry · Quotation · Partnership

➊
点击右上角「···」
选择「发送给朋友」
或「分享到朋友圈」

分享到微信

QR Code

请用微信扫描二维码